GENFIT TO PARTICIPATE AT TWO INTERNATIONAL CONFERENCES IN SAN FRANCISCO ON JANUARY 9-12, 2012
Lille (France), Cambridge (Massachusetts, United States), December 19, 2011 - GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces its participation at the JP Morgan Healthcare Conference 2012 and the Biotech Showcase 2012, both taking place in San Francisco on January 9-12, 2012.
During these two major events dedicated to meetings with the pharmaceutical and specialized financial communities, Jean-François Mouney, CEO of GENFIT, will outline the Company's perspectives, as well as the latest pre-clinical and clinical data for GFT505 in NAFLD/NASH - hepatic complications of Type 2 diabetes with unmet medical needs - for which GENFIT expects to confirm its position as a world leader.
About GENFIT:
GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases.). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI, SERVIER, .), to address these major public health concerns and their unmet medical needs.
GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.
With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext(TM) Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com
Contacts:
GENFIT
Jean-François Mouney - CEO & Chairman of the Management Board
+33 (0)3 2016 4000
Milestones - Press Relations
Bruno Arabian
+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 - barabian@milestones.fr
